Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease

University of Maryland Baltimore (UMB)

Status: Completed

Conditions: Anemia; Chronic Kidney Disease; Cardiomyopathy

Treatments: Drug: Darbepoetin alfa

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT00883415

HP-00041025

Amgen ISS#20061907

Details and patient eligibility

About

This study examines patients with chronic kidney disease-related anemia and measures changes in the metabolism of the heart using FDG/PET scanning, before and 6 months after their health-care provider has initiated anemia management therapy with the FDA-approved drug darbepoetin alfa (Aranesp), which is approved for chronic kidney disease-related anemia. The investigators hypothesize that the heart has abnormal metabolism with the anemia of chronic kidney disease but this improves after correction of this anemia with darbepoetin alfa.

Enrollment: 20 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participant must receive care at the VAMHCS (VA Hospital) in Baltimore
• Diagnosed with CKD stage 3 to 5 (eGFR of 60 ml/min/1.73m2) and not expected to initiate renal replacement therapy within 6 months
• Anemia related CKD.
• The last 2 serum hemoglobin (Hb) values less than 11.0 gm/dl but greater than 8.0 gm/dl
• Greater than 18 years of age
• Assessed to be clinically stable by the clinician

Exclusion criteria

• Need for hemodialysis, peritoneal dialysis, or transplantation at the time of enrollment or projected to start within 6 months after enrollment
• Low functional capacity including inability to walk a flight of stairs with a bag of groceries (NYHA Class III/IV Heart Failure)
• Prior erythropoietic agents within last 12 weeks
• TSAT < 15% and not receiving the recommended dose for iron deficiency
• Uncontrolled hypertension defined as greater than 180 mm Hg systolic or 110 mm Hg diastolic
• Potentially "brittle" diabetes with the propensity for symptomatic hypoglycemia after a 6 hour fast
• New diagnosis or ongoing therapy for Cancer
• Pregnancy